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ABSTRACT 
microRNAs (miRNAs) are single stranded non-coding RNAs of about 22 nucleotides that  have  been 
reported to be involved in various biological processes like embryonic development, cell proliferation, 
differentiation, apoptosis, developmental timing etc. The role of miRNAs as tumor suppressors/oncomiRs 
has been reported in many cancers. In this study, we performed genome-wide expression analysis of 
miRNAs as well as mRNAs in cervical cancer and obtained 257 up-regulated and 81 down-regulated 
mRNAs as well as 27 up-regulated & 14 down-regulated miRNAs. Enrichment analysis of differentially 
expressed mRNAs of cervical cancer revealed CYR61 (cysteine-rich, angiogenic inducer, 61) as a key 
gene involved in vascularisation of the tumors. This CYR61 was found to harbor target sites (7mer-m8) for 
hsa-miR-221 as inferred from TargetScan predictions. From qRT-PCR study in HeLa cell lines, we found 
that CYR61 is over-expressed, whereas hsa-miR-221 is down-regulated in cancer system. The altered 
expression of CYR61 might be due to down-regulation of hsa-miR-221 as this miRNA has target sites 
within 3/UTR of CYR61 which can be further confirmed by luciferase reporter assay. We hypothesize that 
hsa-miR-221 might be playing a role in metastatic spread and lethality in cervical cancer by altering the 
expression of the corresponding mRNA through RNA interference mechanism. Moreover, it can be 
expected that the altered expression of hsa-miR-221 may be due to promoter hypermethylation of the 
miRNA gene or through targeting by other non-coding RNAs, such as lncRNAs which need further studies 
in future. 
 
Keywords: microRNAs, CYR61, angiogenesis, cervical cancer, metastasis, DNA methylation 
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Cancer is an emerging class of disease characterized by out-of-control cell growth where some of 
the somatic cells ‘deny to die’ and invade other tissues. Several check points or quality controls are 
employed in order to prevent uncontrolled proliferation of cells. The normal cells prefer to commit suicide 
when these cells could not pass through the quality controls, however this does not happen in case of 
malignancy. The abnormal and uncontrolled cell growth becomes harmful for the body when the affected 
cells divide rapidly to form lump of cells called tumors. These tumors in turn interfere in the normal cell 
metabolisms and spread to other parts of the body through circulatory and lymphatic systems. Till now, 
more than 100 cancer types have been reported and characterized. 
All cancers begin from the basic unit of life i.e cell. For well understanding of cancer, it is better to 
know what actually happens when normal cells become cancerous. In case of normal cell types, they grow 
and divide in a controlled way to keep the body healthy. As they grow older or damaged, they prefer to die 
and are replaced by the newer ones. However, sometimes the orderly process goes deviated when the 
genetic material of the cell (DNA) become damaged, producing mutations and ultimately affecting normal 
cell growth and division. 
          Dys-regulation of the gene networks involved in maintaining healthy cellular identity, growth and 
differentiation result in diseases like cancer. A very tiny proportion of cancer is the result of inheritable 
single-gene disorder that involves non-synonymous mutation in the coding sequence of mRNA transcript 
such as BRCA1 in breast cancer and Rb1 in retinoblastoma (Cheetham et al., 2013). As a result of this, 
cells don’t die when they should and new cells tend to form when they are not supposed to be created, 
leading to formation of mass of tissues called tumors.  
Tumors that are found to be non-motile i.e do not spread to other parts of the body and are 
characterized by limited growth are known as benign tumors. Other type of tumors is a malignant tumor 
which is motile and invades nearby tissues and spread to different parts of the body. This spread of 
malignant tumor/cancer is known as metastasis. Cancers can be classified depending on their place of 
origin. These are – (i) Carcinoma- cancer of epithelial origin like skin or tissues that cover internal organs. 
The subtypes of this category include adenocarcinoma, basal cell carcinoma, squamous cell carcinoma 
and transitional cell carcinoma etc. (ii) Leukemia- cancer of blood cells or blood-forming cells such as bone 
marrow. (iii) Lymphoma- cancer of immune cells. (iv) Sarcoma- cancer of mesenchymal origin. (v) CNS 
cancer- cancer of central nervous system i.e cancer that begin in the tissue of the brain and spinal cord.  
For the metastatic spread of malignant tumors, supply of vascular network is very important. The 
processes by which new blood vessels are formed and lymphatic system is established are called 
angiogenesis and lymhangiogenesis respectively. Both have essential role in the growth and maintenance 
of cancer cells by providing nutrients, oxygen and removing waste products. These phenomena are now 
getting special attention in the field of neoplastic vascularization. Without the vascular support, the tumors 
may become necrotic and apoptotic. Vascularization is basically a four step process- first, there will be 
occurrence of local injury to the basement membranes, then  angiogenic factor migration causing 
endothelial cells activation followed by proliferation and stabilization and finally the angiogenic factors 
continue to influence the angiogenesis process (Nishida et al., 2006).  
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The potentiality of the cancer cells to multiply independently of exogenous growth inhibitory or 
growth promoting signals, invade nearby tissues and metastasize, exhibit angiogenic response, evade 
program cell death and cellular senescence are the reflection of altered cell signaling pathways. Current 
research strategies are mainly based on the signaling molecules that are supposed to elicit potential 
response in these pathways. 
        The cancer of prostrate, breast, lungs, colon/rectum and cervix account for more than half of the 
cancer cases. In developing countries, cervical cancer is the second largest class of malignant tumors 
which endangers the woman’s health (Lei et al., 2012). It is the cancer of cervix (the connecting organ 
between uterus and vagina) and is generally slow growing. This cancer usually doesn’t show any 
symptoms and can only be detected through regular pap tests (a procedure by which the cervical cells are 
scraped and seen under microscope). 
  Although cervical cancer is mainly caused by prolonged infection with Human papilloma virus 
(HPV), but it has been found that it may arise due to abnormal expression or functioning of oncogenes or 
tumor suppressor genes and/or other factors (Kaczkowski et al., 2012). 
The abnormal expression involves either up or down regulation of genes, achieved by two means- 
Histone/DNA modification & RNA interference (RNAi) mechanism (Wilting et al., 2013a). RNAi mechanism 
is mainly operated by non-coding RNAs (ncRNAs) that cause translational repression or degradation of 
target transcript and thereby alter their normal function. DNA modification mainly occurs through promoter 
hyper or hypo-methylation. An association between chromosomal alteration and differential expression of 
miRNA has been reported in many cancer types such as breast cancer, melanoma, neuroblastoma and 
myeloma. It has been reported that the miRNA exhibits its regulatory mechanism through inhibition of 
mRNA translation or direct degradation of the coding transcript thereby promoting the development of 
cervical cancer. The microarray analysis performed by them indicated that there are a large number of 
differentially expressed miRNAs as well as mRNAs in cervical cancer, which together promote its 
occurrence and development (Ma et al., 2012). 
The significance of DNA methylation and its impact on gene activity in many cancers have been 
studied. The frequency of promoter methylation has been found in case of many tumor supressor genes in 
cervical cancer as well. The p16 gene that play a key role in controlling cell cycle progression has been 
reported to be progressively methylated in 31% of the cervical cancer cases. There are also reports of  
methylation in other genes such as FHIT and GST enzyme families that accounts for 20-30% of cervical 
cancer cases (Virmani et al., 2001). 
Proper understanding and unrevealing the mystery of this cancer progression and the effect of the 
above described control mechanisms on various key transcripts can provide a better way for the 
therapeutic prevention of this deadly disease. Metastasis is the main cause of invasion and spreading of 
cancers including cervical cancer and angiogenesis is the key mechanism involved in this process 
contributing to lethality of the cancer. Therefore, we have chosen some key regulatory genes involved in 
various signaling pathways promoting angiogenesis which will be helping in cancer progression. By 
exploring the control mechanism responsible for the abnormal expression of these transcripts involved in 
angiogenesis and signaling pathways might provide some effective preventive major of this cancer. We 
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executed this project by studying the differentially expressed transcripts and miRNAs and the cross-talks 
among them by amalgamating microarray analysis, miRNA target prediction, miRNA-mRNA interaction 
studies with experimental validation of selected mRNAs involved in angiogenesis and miRNA proposed to 
be regulating these genes in HeLa cell line (test) and HaCaT cell line (control).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
REVIEW OF LITERATURE 
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Cancer 
Cancer is a multistep process in which cells acquire their ability to proliferate uncontrollably and 
undergo metastasis. The crucial steps involved in transformation of normal cells in to malignant type are 
the ability of the cells to be self-sufficient and unresponsiveness to the growth-limiting signals (Hanahan 
and Weinberg, 2000). The abnormal behavior exhibited by the cancer cell that distinguishes itself from 
normal cell type is the result of accumulated abnormalities in diverse regulatory systems. As cancer can 
arise from uncontrolled proliferation of any kind of cells in the living system, so there exist more than 100 
distinct types of cancer those vary in their regular behavior and response to the conventional therapies. 
Distinction between benign and malignant tumors is one of the most importance aspects of cancer 
pathology (Fig.1). 
 
 
Fig.1. Progressive stage of cancer from benign to malignancy (adopted from-
www.hopkinscoloncancercenter.org). 
 The marked region for benign shows hyper proliferative and non-motile tumors and that for malignant 
shows invasion and migration of the tumors in to the blood stream. 
A tumor that remains confined to its original location, incapable of spreading or invading to the 
nearby tissues is known as benign. These are mostly like common skin warts. A malignant tumor on the 
other hand is capable of invading neighboring cells as well as distant normal tissues and thus spreads 
throughout the body with the help of circulatory or lymphatic systems. The spreadability of the cancer 
through these circulatory or lymphatic systems is known as metastasis, the only cause of most cancer 
lethality. The malignant tumors are mainly considered as cancers with the ability to metastasize (GM). 
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Types of cancer  
Both the malignant and benign tumors are categorized according to their cells of origin. Most cancers 
can be systematized in to the following main groups (Fig.2)- 
 Carcinomas 
 Sarcomas 
 Leukemia 
 Lymphomas 
 CNS cancers 
 
 
 
 
 
 
 
 
Fig.2. Different cancer types (adopted from-HEALTH LIBRARYweb.iadmd.org) 
 
 Carcinoma- It accounts for approximately 90% of human cancers and are the malignancies of cells 
of epithelial origin. The subtypes of this category include adenocarcinoma, basal cell carcinoma, 
squamous cell carcinoma and transitional cell carcinoma etc. Depending on the tissue of origin 
these can be further classified accordingly such as Breast cancer, Lung cancer, colon cancer etc. 
 
 Sarcoma- These are solid tumors of connective tissues or cancer of mesenchymal origin such as 
muscle, cartilage, fibrous tissues (fibrosarcoma) and bones. 
 
 Leukemia- These are cancer of blood cells or blood-forming cells such as bone marrow which 
account for approximately 8% of human malignancies. Other examples of this cancer type are 
Erythroid leukemia arising from the red blood cells. 
 
 Lymphoma- These are cancer of cells from immune system that arises from lymph-nodes 
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 CNS cancer- These are cancer of central nervous system i.e cancer that begin in the tissue of the 
brain and spinal cord (GM).  
Hallmarks of cancer 
Irrespective of the diverse types of cancer, there exists some idiosyncrasy that makes the cancer well 
distinguishable from normal cells. There exist various hall marks (Fig. 3) that enable metastatic growth and 
allocate solid foundation for understanding the biology of cancer (Hanahan and Weinberg, 2011). 
 
 
 
 
 
 
 
 
 
 
     Fig. 3. Different Hallmarks of cancer 
 
Metastasis and Cancer 
Adaptation of the unstable malignant cells to a new microenvironment that is away from their origin 
is considered as metastasis. In due course of metastasis, some beneficial traits are selected that helps 
invasion as well as the survivability and stability of cancer cells. Recent understandings related to the origin 
and nature of cancer metastasis has been improved by new advanced technologies. Although the actual 
cause behind the mechanism that how the malignant tumors spread throughout the body and kill the host is 
not known, but the cancer biologists have predicted that it might be due to interplay between rambling 
tumor cells with their bialable target tissues. The mechanism about how tumor cells enter to metastasis 
through changing their own microenvironment, entering to the circulatory or lymphatic system, and finally 
colonizing at the distant tissue has been less explored till to date, irrespective of the fact that it is the crucial  
cause of more than 90% of deaths because of solid tumors. Recent studies indicate that, metastasis may 
occur due to genomic instability because of some oncogenic events like evasion of growth suppression or 
DNA damage check points (Gupta and Massague, 2006). 
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The steps involved in biological cascade of metastasis mainly include- loss of cellular attachment, 
transition, invasiveness, entry to the circulatory system and colonization at a distant tissue sites (Chambers 
et al., 2002). Recent works based on the genomic-level molecular profiling have unrevealed some key 
regulatory genes whose expression in primary tumor state and the metastatic state are  found to be 
strongly co-related (Weigelt et al., 2005). These observation has provided some clue to find out how, where 
and when the cancer cells acquire the relevant genes to undergo metastasis in diverse cancer types 
(Bernards and Weinberg, 2002). 
Metastasis takes place as a result of progressive implication of traits that enable the cancer cells to 
go for migration and invasion at the secondary site (Fig.4). All the these traits not necessarily should follow 
this particular order but the factors responsible for each step may facilitate the execution of multiple steps 
simultaneously (Gupta and Massague, 2006). It is also possible that the rate limiting steps for this 
metastatic progression may also vary from diverse tumor types.  
 
Fig.4. Stages of metastatic progression (adopted from (Gupta and Massague, 2006) 
Cervical cancer 
Cervical cancer is a carcinoma of cervix, the joining between uterus and vagina. Cervix is the lower and 
narrow part of vagina situated in the pelvis that constitute the major portion of the female reproductive 
system (Fig.5) (Elst et al., 2007). The cervix is considered as a gateway because-  
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• It connects the uterus with vagina. During the menstrual period, blood flow from the uterus, move to 
the vagina and finally to the outside. 
• Mucus secreted by the cervix help in the entry of sperm in to uterus through vagina during sexual 
intercourse. 
• In due course of pregnancy, cervix remains tightly closed to keep the baby inside the uterus and 
opens to allow the baby to pass through the vagina during childbirth. 
  
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Overview of Cervix (adopted from www.ncis.com.sg) 
 
There are two categories of cervical cancer- 
Squamous cell cervical cancer (Ectocervix) - This type of cervical cancer arises when the flat fish scale like 
cells present on ectocervix region become malignant. Ectocervix also known as portio vaginialis is the 
portion of cervix that projects in to the vagina.  
Cervical adenocarcinoma (Endocervix) - It arises in the inner lining of the cervix that are covered by 
glandular cells leading to adenocarcinoma of the cervix. 
The region of Endocervix contains the transformation zone (most prone region to develop the cancer) 
situated in the endocervical canal. During the screening for cervical cancer, this region is mainly studied by 
the doctors (Elst et al., 2007) 
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Symptoms of Cervical cancer 
Similar to many other cancer types, patients generally experience no symptoms at the early stages. 
Therefore, it is always advised to women to have regular cervical smear tests. At later stages, patients 
experience some symptoms like- 
• Excessive vaginal bleeding after sexual intercourse, douching( cleaning out of vagina with water or 
some specific fluid to avoid sexually transmitted diseases especially done during pregnancy to avoid 
any kind of infection) or any kind of pelvic examination. 
• Durable and heavy menstrual periods. 
• Heavy vaginal bleeding even after going through menopause. 
• Increased and smelly vaginal discharges sometimes mixed with blood. 
• Pelvic pain and pain during sex (Garner, 2003) 
 
Stages of cervical cancer 
 Most cancers spread from their primary location to the other mainly through lymphatic or circulatory 
systems or invading through the tissues. Malignant cells spread through the tissues by growing to nearby 
areas, while spreading through lymph systems they move through the lymph vessels and similarly travels 
through the blood vessels after entering to the circulatory system. Depending on the extent of cancer 
spread from the cervical region to other parts of the body, there are many stages found according to the 
survey by the National Cancer Institute. These are as follows- 
Stage 0: 
At this stage, the abnormal cells are localized to the innermost lining of cervix which may become 
cancerous and invade to the other part of the body in due course of cancer progression. 
Stage I: 
During this stage, cancer is found in the cervix only and depending on the amount of cancer found it can be 
further classified in to two sub-stages such as stage IA and IB (Fig.6). At this stage, The cancer cells can 
only be visualized through microscope. The cancer cells at stage IA1 and IA2 are found to be 3-5 
millimeters deep and 7 millimeters wide. 
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Fig. 6. The Stage I of cervical cancer (adopted from-
http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page2) 
At the stage IB1 and IB2, the cells can be seen without microscope and are more than 5 millimeters 
deep, more than 7 millimeters wide . 
Stage II: 
In stage II, cancer cells tend to spread beyond the cervix, but not up to the pelvic wall or lower part of 
vagina. It can be further divided to IIA or IIB (Fig. 7) depending on how far the cancer has been spread. In 
stage IIA (IIA1 & IIA2), the cancer cells spread  up to the two thirds of vagina  but not till the uterine region, 
while in stage IIB, cancer tend to move to the tissues around the uterus. 
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Fig.7. The Stage II of cervical cancer (adopted from-
http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page2) 
Stage III: 
In this stage, cancer has spread to the lower part of vagina, to the pelvic wall. Some kidney disorders are 
found at this stage and can be classified to IIIA or IIB (Fig. 8) depending on how far the cancer cells have 
migrated. At this stage the tumor cells become large enough to block the uterus as a consequence kidney 
starts enlarging and stop functioning. 
 
  
 
 
 
 
 
 
Fig. 8. The Stage III of cervical cancer (adopted from-
http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page2) 
Stage IV: 
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At this stage, cancer starts migrating to the other parts of the body. Based on the localization of the cancer, 
this stage can be divided in to sub-stages like IVA (bladder, rectum) or IVB (liver, lungs, and bones) (Fig. 
9). 
 
 
 
 
 
 
 
 
 
Fig. 9. Stage IV of cervical cancer (adopted from-
http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page2) 
Causes of Cervical cancer 
  There are many factors reported that are known to increase the risk of cervical cancer as surveyed 
by National cancer Institute (NCI). 
HPV (Human papilioma virus) infection:  
The virus is a sexually transmitted virus of 100 different kinds, out of which 15 types are known to cause 
cervical cancer. It has been found that the HPV type 16 and 18 are known to cause approximately 70% of 
cervical cancer cases and type 6 & 11 cause 90% of genital warts. Other HPV types may promote the 
growth of abnormal cells on the surface of cervix causing cervical intra-epithelial neoplasia (CIN). 
Multiple sexual partners: 
The HPV causing the cervical cancer are mainly transmitted due to sexual contacts with the infected 
person. Therefore, it is expected that the woman having many sexual partners are generally tend to 
possess high risk of cancer through infection with HPV. 
Smoking: 
Like other cancers, smoking is known to increase the risk of cervical cancer possibly through weakening 
our own immune system. 
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Suppressed immune system: 
Persons suffering from diseases like HIV/AIDS that weaken the host’s immune system, are mostly in higher 
risk of having this cancer. This is also seen in individuals who have taken immune suppressive drugs 
during any transplantation therapy. 
Giving birth at an early age or having several pregnancies: 
Women who have given birth to child at very early age like 17 are supposed to have high risk for cervical 
cancer as compared to the lady who has undergone pregnancy after the age of 25. Repeated and several 
pregnancy also have shown to increase the risk of this cancer. 
Other sexually transmitted Disease: 
Women having infection with Chlamydia, gonorrhea or syphilis are highly sensitive to develop cervical 
cancer. It has been found by scientists at the Medical university of South Carolina that HPV infection 
becomes long lasting in presence of  Chlamydia. 
Other factors like long term mental stress, continuous use of contraceptive pills, socio-economic status also 
contribute to the higher probability of being infected with cervical cancer. 
Other genetic and epigenetic causes: 
Besides these factors associated with cervical carcinogenesis, other genetic and epigenetic factors 
also promote the cervical carcinogenesis. These factors are include DNA or Histone modification or the 
regulatory mechanism exhibited by the RNA interference which alter the normal functioning of various 
genes involved in diverse biological processes like cell cycle regulation, growth arrest, angiogenesis, 
metatstasis, tumor suppression etc. These abnormal functioning helps the tumor cells to proliferate 
uncontrollably by increasing their stability. 
The integrated genome analysis of Squamous cell carcinoma (SCC) and Adenocarcinoma (AdCs) 
conducted by Wilting et al identified 83 differentially expressed genes in comparison with normal 
epithelium. They also identified chromosomal hot spots where the gain or loss at those chromosomes leads 
to alteration in expression of the corresponding genes viz. chromosomal gains at the arm of chromosome 
1, 3, and 20 leads to over expression of the genes (DTX3L, PIK3RA, ATP2C1 and SLC25A36)   located at 
1q32.1-32.2, 3q13.32-23, 3q26.32-27.3, and 20q11.21-13.33 whereas loss in chromosome at 11q22.3-25 
were related with low activity of those associated genes (Wilting et al., 2008). In another study, it was 
reported that alteration of mRNA expression  that codes for sialytransferase was found to be associated 
with cervical carcinogenesis (Wang et al., 2001). Besides these genetic factors, the epigenetic control 
mechanisms comprising mainly of DNA/Histone modification and RNA interference are also known to be 
involved in carcinogenesis. 
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DNA/Histone modification: 
The process of oncogenesis depend on the switch on/off activity of two different set of genes- Tumor 
supressor genes and oncogenes regulating different aspects of cell growth and survival. The alterations in 
these genes are essential for the malignancy and are probably modulated by either of the epigenetic 
changes. Epigenetic changes are heritable changes in the gene activity that are not supposed to be caused 
by alteration in the primary DNA sequence. These epigenetic modification may comprises of  - covalent 
modification of some amino-acid residue of the histone protein that helps in close packing of DNA 
maintaining its heterochromatin state; methylation or acetylation or phosphorylation or sumoylation on the 
DNA itself. Methylation is  carried out by enzymes like  DNA methyl transferases (DNMT) that cause 
methylation at the specific regions of promoter known as CpG island (Fig. 10) (repeated cluster of CG 
dinucleotides) thereby suppressing the corresponding gene transcription. Gene silencing can also be 
reversible through other epigenetic mechanism like acetylation of histone which results in decondensation 
of chromatin network and reestablishment of the transcriptional machinery by the addition of acetyl group to 
the Lysine residue of histone and distorting the nucleosomal structure. This aspect of epigenetic alteration 
in the functionality of various transcripts are now getting more attention and have become the therapeutic 
target in various disease systems including cancer (Gronbaek et al., 2007).  
  
 
Fig. 10.  DNA modification through methylation at the CpG island 
 
DNA methylation is not only restricted for the regulation coding transcripts, there are also reports where 
they have been found to regulate the expression of noncoding RNAs thereby altering their expression 
pattern in many cancer systems including cervical. Such study was done by a group of scientists where 
they have found that the frequent down regulation of miR-203 was because of  methylation at miR-203 
promotor, thus promoting cervical tumorigenesis(Zhu et al., 2013). 
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 Another  approach in this aspect to find out the impact of  methylation on the activity mRNAs in 
cervical cancer have  shown hypermethylation  miR-432, -1286, miR -1290, miR-128 and miR-95 with 
respect to HPV-infection (Yao et al., 2013). miR-214 that has been previously reported to inhibit cell growth 
and metastasis, further analysis  has shown that  the expression of this miRNA was correlated with 
expression of Bax, caspase-9 & 8 and is itself regulated by DNA methylation and histone deacetylation 
(Wang et al., 2013a). In an another study, deregulation of miR-149, miR-203 and miR-375 were found to be 
mediated by DNA methylations of the respective miRNA genes (Wilting et al., 2013b). 
RNA interference: 
RNA interference refers to the post transcriptional gene silencing mechanism operated by different 
kinds of RNA molecules. RNAs are mainly comprised of many coding as well as non-coding RNAs 
(ncRNAs) that interfere in the activity of other coding transcripts. The ncRNAs include small non-coding 
RNAs (miRNA, siRNA, piRNA etc) and long non-coding RNAs (lncRNA). The ncRNAs are involved in 
specific gene silencing or gene regulatory mechanisms (Gomes et al., 2013). Recent studies have shown 
that among the three types of small ncRNAs, miRNA have some pivotal role in normal cell metabolism and 
its differential expression is supposed to have diagnostic and prognostic value in many cancer cases 
including cervical cancer (Lui et al., 2007). 
miRNAs  are single stranded RNAs of 22 nucleotide in length, generated from double stranded 
hairpin shaped RNA precursors with the help of RNase-III enzyme (Bartel, 2004). These small ncRNAs 
exhibit their mode of action through post transcriptional gene silencing either by target RNA cleavage or 
translational repression of the target transcript (Fig.11) in association  with RNA inducing silencing complex 
(RISC) thereby importing dramatic effects on cellular phenotypes (Filipowicz et al., 2005). 
 
 
 
. 
 
 
 
 
Fig.11. Mechanism of action of microRNA 
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The complementarity between the seed region of miRNA and with that of target mRNA has a pivotal role in 
miRNA-mediated gene regulation through miRNA targeting. There exist mainly three kinds of conventional 
target binding sites such as canonical sites, marginal sites and atypical sites (Fig. 12). In the canonical 
sites, the binding mainly occurs between 2-7 or 2-8 ntds position on the miRNA, while for marginal sites it 
lies in between 2-7 or 3-8 ntd positions. The supplementary sites are located at 12-17 position in addition to 
the seed region with complete Watson-crick base pairing. But compensatory binding sites are seen in 
between 12-19 position with respect to wobble base pairing in the traditional seed sites in order to 
compensate the mismatch (Bartel, 2009). 
 
 
 
 
 
Fig.12. Types of miRNA target sites (adapted from (Bartel, 2009) 
 
Role of miRNA in Cervical tumorigenesis: 
  The mature miRNA induce posttranscriptional gene silencing in association with RISC complex by 
binding to the complementary motifs on the 3’UTR (untranslated regions) of the target transcript (Fabian 
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and Sonenberg, 2012). As miRNA has the ability to target up to several mRNAs, therefore aberrant 
expression of miRNAs can have profound influence on specific genes thereby affecting cancer-associated 
signaling pathways (Wightman et al., 1993). 
  The miRNA profiling study in many tumor types suggested that they are found to have altered 
expression in many cases thereby by changing the expression pattern of the target transcript and further 
downstream signaling mechanisms. One study in such aspect have shown that, miR-29 acts as a tumor 
supressor  in lung cancer, while in Breast cancer it was found to be involved in oncogenesis (Fabbri et al., 
2007; Gebeshuber et al., 2009). Other reports like- down regulation of miR-26a was associated with 
hepatocellular carcinoma (Kota et al., 2009). Likewise  in cervical  cancer systems, many altered miRNAs 
have been found through genome wide miRNA expression profiling (Wilting et al., 2013a) and are listed as 
follows Table 1. 
Table 1. List of differentially expressed miRNAs in Cervical intraepithelial neoplasia (CIN) and/or  
Squamous Cell Carcinoma (SCC) vs. normal Squamous epithellium (Wilting et al., 2013a). 
Up-regulated miRNAs Down-regulated miRNAs
  
hsa-miR-192      
hsa-miR-135 
hsa-miR-101 
hsa-miR-191 
hsa-miR-34 
hsa-miR-150 
hsa-miR-125 
hsa-miR-30 
hsa-miR-143 
hsa-miR-146 
hsa-miR-181 
hsa-let-7 
hsa-miR-26 
hsa-miR-29 
hsa-miR-10 
hsa-miR-145 
hsa-miR-425 
hsa-miR-205 
hsa-miR-27 
hsa-miR-212 
hsa-miR-770 
hsa-miR-484 
hsa-miR-636 
hsa-miR-494 
hsa-miR-125 
hsa-miR-375 
hsa-miR-99 
hsa-miR-188 
hsa-miR-148 
hsa-miR-671 
hsa-miR-199 
hsa-miR-51 
hsa-miR-378 
hsa-miR-195 
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hsa-miR-24 
hsa-miR-331 
 hsa-miR-151 
hsa-miR-151 
hsa-miR-107 
hsa-miR-17* 
hsa-miR-9 
hsa-miR-185 
hsa-miR-339 
hsa-miR-18 
hsa-miR-7 
hsa-miR-17 
hsa-miR-130 
hsa-miR-15 
hsa-miR-106 
hsa-miR-19 
hsa-miR-200c 
hsa-miR-20 
hsa-miR-363 
hsa-miR-155 
hsa-miR-141 
hsa-miR-93 
hsa-miR-15 
hsa-miR-16 
hsa-miR-28 
hsa-miR-338 
hsa-miR-206 
hsa-miR-17* 
hsa-miR-9 
hsa-miR-185 
hsa-miR-339 
hsa-miR-18 
hsa-miR-486 
hsa-miR-376 
hsa-miR-497 
hsa-miR-100 
hsa-miR-660 
hsa-miR-218 
hsa-miR-203 
hsa-miR-638 
hsa-miR-370 
hsa-miR-575 
hsa-miR-193 
hsa-miR-572 
hsa-miR-149 
hsa-miR-210 
hsa-miR-622 
hsa-miR-23 
hsa-miR-493 
hsa-miR-296 
hsa-miR-617 
hsa-miR-134 
hsa-miR-365 
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Above mentioned altered miRNA profiling data clearly indicates that the corresponding targeted 
mRNA expression may also be altered in cervical cancer system. Many more studies have been carried out 
on this aspect in this cancer system. Recently, the  CHL1 (a cell cycle regulator) gene was found to be 
targeted and silenced  by overexpressed miR-590-5p and thus promoting cervical cancer cell growth and 
survival (Chu et al., 2014). In another similar kind of study, it was found  that the overexpression of COX-2 
gene in cervical cancer leads to cell proliferation and migration due to loss of regulation by miR-101 (Huang 
et al., 2013). 
Moreover, it has also been found that down regulation of miR-506 was inversely correlated with KI-
67 expression, a marker for cell proliferation in cervical cancer (Wen et al., 2014). In another approach, 
miR-181b has been seen promoting cell proliferation and inhibiting programmed cell death by targeting 
adenyl- cyclase 9 thereby restricting cAMP production in cervical cancer (Yang et al., 2014). Recent 
research has uncovered the role of miR-196a in cervical cancer proliferation and migration as a oncogenic 
inducer  by inhibiting the expression of  netrin4 (NTN4)mRNA (Zhang et al., 2013). 
Another reverse interaction study between octamer-binding transcription factor 4(OCT4)mRNA and 
miRNA-125b has indicated that , OCT4 induces the up regulation of the miRNA by binding to its promoter 
and the overexpression of miR-125b  reduces the activity of BAK1(another transcript  ) as a result reducing 
cell apoptosis  in primary cervical cancers (Wang et al., 2013b). 
Another study has demonstrated the role of miR-7 in cervical cancer. Over expression of this 
miRNA resulted in reduced cell viability regulating the expression of an oncogene XIAP(X-linked inhibitor of 
apoptosis protein)  (Liu et al., 2013).  Over expression of miR-125b  in cervical cancer cells has been 
reported that results  in low expression of phosphoinositide 3-kinase thereby inducing apoptosis and 
decreasing cell proliferation (Cui et al., 2012).  
Recently it has been reported that, miR-99a and miR-99b were found to be down regulated in 
cervical cancer tissues and are found to target mTOR-gene thereby negatively inducing metastasis (Wang 
et al., 2014). Based on these observations, we have hypothesized and have found a novel miRNA and its 
potential target transcript which is basically an angiogenesis inducing factor, playing crucial role in 
metastasis of malignant 
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OBJECTIVE 1 
Transcriptional profiling analysis of differentially expressed mRNA in cervical 
cancer 
 
OBJECTIVE 2 
Identification of differentially expressed miRNA in cervical cancer 
 
OBJECTIVE 3 
Identification of miRNA-mRNA interaction network operating in cervical 
cancer using NCI pathway analysis database, targetscan software. 
 
OBJECTIVE 4 
Experimental validation of the selected pairs of mRNA-miRNA in the cervical 
cancer by qRT-PCR 
 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS 
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Gene Expression data: 
The expression profiles of mRNAs as well as miRNAs in different stages of cervical cancer were 
retrieved from GEO database of NCBI. GEO provides a flexible and open design that facilitates submission, 
storage and retrieval of heterogeneous data sets from high-throughput gene expression and genomic 
hybridization experiments such as microarray. The three central data entities of GEO are platforms, 
samples and series, and were designed with gene expression and genomic hybridization experiments. The 
gene expression data are generally generated by microarray hybridization experiments that represent the 
expression of specific genes in a particular system. Microarray is a powerful technology for biological 
exploration which enables to simultaneously measure the level of activity of thousands genes.  
  Gene expression data are generated and stored in databases like GEO (Gene Expression 
Omnibus), GXD(Gene Expression Database), Gene Expression Atlas etc. For our study the microarray 
data were retrieved from GEO database which is the well known depository of functional genomic data. The 
data were retrieved for both normal (control) tissues and cancerous (test) tissues of cervical origin from 
different records (GSE) of GEO database. GSE records are comprised of specific experiments constituting 
individual samples called GSMA sample describes the set of molecules that are being probed and references a 
single platform used to generate its molecular abundance data. A series organizes samples into the meaningful data 
sets which make up an experiment Experimental data were obtained by selecting two GSE records , that were  
GSE-7803 for mRNA data analysis and GSE-30656 for microRNA. 
GSE-7803 
 This Experiment was based on the expression profiling by array, taking 10 normal Squamous cervical 
epithelia sample and 21 invasive squamous cell carcinoma. The platform for data was Affymetrix HG-
U133A with GEO platform accession number GPL96.  A platform is, essentially, a list of probes that define 
what set of molecules may be detected.  From the above mentioned GSE, individual GEO samples (GSM) 
were selected and are shown as follows 
GSM189381,  GSM189382,  GSM189383,  GSM189384,  GSM189385,  GSM189386,  GSM189387,  GSM189388, 
GSM189389, GSM189390, GSM189391, GSM189392,  GSM189393 for Normal squamous cervical epithelia  
 
GSM189401,  GSM189402,  GSM189403,  GSM189404,  GSM189405,  GSM189406,  GSM189407,  GSM189408, 
GSM189409,  GSM189410,  GSM189411,  GSM189412,  GSM189413,  GSM189414,  GSM189415,  GSM189416, 
GSM189417,  GSM189418, GSM189419, GSM189420, GSM189421 for Invasive squamous cell carcinoma. 
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GSE-30656 
This Experiment was based on Non-coding RNA profiling by array, taking 47 samples such as 10 
Squamous cell carcinoma and 10 cervical squamous epithelial samples.  
The platform for data was Affymetrix HG-U133A with GEO platform accession number GPL6955. From the 
above mentioned GSE, individual GEO samples (GSM) were selected and are shown as follows: 
GSM760511, GSM760512, GSM760513, GSM760520, GSM760521, GSM760538, GSM760539, 
GSM760540, GSM760546, GSM760547 for Squamous cell carcinoma. 
GSM760507, GSM760508, GSM760509, GSM760510, GSM760541, GSM760542, GSM760543, 
GSM760548, GSM760549, GSM760550 for cervical Squamous epithelial samples. 
 
The process of retrieving the data from GEO is as follows: 
GEO profile database of NCBI was selected and searched for studies relevant to our interests 
 
Raw data was downloaded from the provided supplementary files with each GSM at the end of the 
section in .CEL format 
                    
                     Downloaded files were then unzipped 
                  
                  Files were then renamed as control and test 
 
The files were then imported in to GeneSpring software for further statistical analysis 
 
Analysis of gene expression data 
We have used Genespring GX software (Genespring GX 11; Agilent, Santa clara, CA) for analyzing 
the gene expression data. This software provides powerful and accessible statistical tools for high-speed 
visualization and analysis of transcriptomics, genomics, proteomics and metabolomics data. It is an user 
friendly software that provides the user an interactive computing environment for well understanding of the 
microarray data in biological context. This software provides an integrative platform for any kind of data 
analysis. Some unique features of this software includes Gene-level expression analysis on diverse 
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platform such as Agilent, Affymetrix and Illumina, microRNA analysis and their potential targets, correlative 
analysis of miRNA and mRNA expression, real-time PCR data analysis etc. 
 We adapted some steps while doing gene expression analysis in genespring described as follows: 
1. The raw data files from GEO database were  first downloaded in .CEL format as a zip file. 
2. Then the files were unzipped, extracted and renamed according to convenience. 
3. GeneSpring interface was opened and a new project with new experiment was created. Workflow type 
was selected according to the biological significance. 
4. Data was uploaded in the selected technology as Affymetrix Gene HG-U133A. Profile plot of Normalized 
intensity map values is obtained after Normalization of data. Normalization is done mainly for eliminating 
redundancy and ensuring that the data make sense with minimum number of entities. 
5. The common set of genes obtained was exported along with their normalization values, gene symbol 
and Entrez gene IDs from the GeneSpring software as a tab delimited file for further analysis. 
6. Grouping was done which further includes Addition of parameter, Assigning value etc. 
8. Creation of interpretation was done by choosing  average, Filter probset by error, taking co-efficient of 
variation as 50, Fold change >=1.54 
9. Output was exported  in excel that showed following headings- probset, Fold change (Test/control), Log 
fold change(Test/control),Regulation (up or down) Intensity value, gene symbol, entrez gene id by NCBI. 
10.Using the obtained common set of genes, clustering analysis was done in GeneSpring using 
Hierarchical clustering algorithm. The distance metrics used was pearson uncentered and the linkage rule 
used was average. 
Interaction study by NCI pathway analysis tool 
The National Cancer Institute (NCI) in collaboration with Nature Publishing Group has established 
the Pathway Interaction Database (PID) in order to provide a highly structured, curated collection of 
information about known biomolecular interactions and key cellular processes assembled into signaling 
pathways. The database focuses on the bimolecular interactions that are known or believed to take place in 
human cells. It can be browsed as an online encyclopedia, used to run computational analyses, or 
employed in ways that combine these two approaches. In addition to PID's predefined pathways, search 
results are displayed as dynamically constructed interaction networks. 
For this we selected the down regulated mRNA and run in enrichment analysis test with a web 
based NCI pathway analysis tool. 
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Prediction of miRNA targets using Target scan 
 Target scan is free web based software that predicts biological targets of miRNAs by searching for 
the presence of sites that match the seed region of each miRNA. In mammals, the user can choose 
whether the predictions should be ranked based on the probability of their conservation or on site number, 
type, and context. In mammals and nematodes, the user can also chose to extend the predictions beyond 
conserved sites and consider all sites. 
we searched  the name of the gene and selected the organism as Homo sapiens. Then it showed the all 
probable target binding sites of  miRNAs. 
Experimental validation 
Cell culture 
For our study HeLa cell line was procured from NCCS , those are human cervical cancer cells. HeLa cell 
line is the first type of human cancer cell which were successfully cultured continuously for experimental 
purpose. It was first derived from cervical cancer cells in 1951 from a patient named Henrietta Lacks.  We 
took HaCaT cell line as control as it is a normal epithelial cell line, procured from NCCS. The medium used 
for culturing the Hela  cell was  MEM and that for control was DMEM (Invitrogen with NE A-A (non essential 
amino acids) and L-Glutamine) with 10% FBS (Fetal bovine serum from HIMEDIA) and 1% antibiotic 
solution (Penstrep solution from HIMEDIA). The culture flask containing the cell line is kept in the CO2 
incubator with 5% level of CO2. 
Cell harvesting 
Before harvesting the cells were  seen under microscope. 
At first media was discarded using 1ml pipette and washed with 1ml PBS. 
Then 1ml trypsin was added to the flask and kept for 5min incubation inside the CO2 incubator. 
Then 1ml media was added to neutralize the trypsin and stop the trypsinization process. 
Then the cells were   taken in a separate tube and centrifuged to obtain the pellet for further use. 
All the procedure should be carried out inside the laminar airflow under aseptic condition to avoid 
contamination. 
RNA Isolation 
For mRNA 
RNA isolation was carried out using QIAGEN RNAeasy kit. The steps involved in the isolation of RNA 
were as follows- 
Appropriate volume of RLT buffer was to the harvested cells. 
1 volume of 70% ethanol was added to the lysate followed by mixing through pipettin only. 
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Approximately 700μl of the sample including any precipitate was added to an RNasy mini spin column 
placed in a second collection tube followed by centrifugation for 15s >=8000xg.Flow through was 
discarded. 
Then 700 μl buffer RWI was added to the RNasy spin column and centrifuged at >=8000 xg. Flow through 
was discarded. 
500 μl buffer RPE was added to the column and centrifuged  for 15s at >= 8000 xg. Flow through was 
discarded. 
500 μl buffer RPE was added to the column and centrifuged  for 2min  at >= 8000 xg. Flow through was 
discarded. 
The spin column was placed in a new 1.5ml collection tube. 30-50 μl RNase free water was directly added 
to the spin column membrane followed by centrifugation for 1min at.=8000 xg to elute the RNA. 
For miRNA 
miRNA isolation was carried out using  mirVANA TM miRNA isolation  kit with phenol . The steps involved in 
the isolation of miRNA were as follows  
The harvested cells were first washed with PBS and cell pellet was collected. 
After removing the PBS ,600μl lysis/binding solution was added followed by vortexing to obtain 
homogenous lysate. 
60 μl miRNA homogenate additive was added to the cell mix, mixed well by vortexing and was then kept on 
ice for 10 mins. 
1 volume (600 μl) of Acid phenol-chloroform was added before the addition of miRNA homogenate to the 
lysate followed by vortexing and centeifugation at 10,000 g for 5min to separate the aqueous and organic 
phase at room temperature. 
Then the aqueous phase was carefully removed without disturbing the lower phase and was transferred to 
a fresh tube. 
1.25 volume of 100% ethanol (maintained at room temperature) was added to the aqueous phase. 
The lysate-ethanol mix was placed in to a filter catridge placed in the collection tube  followed by 
centrifugation at 10,000 g for 15 sec. Flow through was discarded. 
700 μl of miRNA wash solution 1 was added to the filter catridge and centrifuged for 5-10 secs. Flow 
through was discarded. 
500 μl of wash solution 2/3 was added and centrifuged for 5-10 secs. This step was repeated for one more 
time and flow through was discarded. 
The filter catridge was again centrifuged to remove the residual volume from the filter. 
The filter catridge was then transferred to a fresh collection tube, 100 μl of preheated (95o C) elution 
solution was added to the centre of the filter and was given short spin for 20-30secs at maximum 
speed to recover the RNA. 
The elluent was then collected and stored at -20o C. 
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Precaution: 
•  A clean and sterilized environment was maintained while working with the RNA as there is high 
chance of contamination by RNase which may degrade the RNA and leading to reduced RNA yield. 
• Gloves should be used while doing the reaction as there is high chance RNA degradation by the 
effect of nuclease secreted from the finger tip. 
cDNA synthesismRNA-cDNA synthesis 
• cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RTPCR by 
Invitrogen using oligo dT primers. 
       The steps in cDNA synthesis are as follows: 
• Each component of the kit was mixed and briefly centrifuge before use. 
• For each reaction, the following components were combined in a sterile 0.2 or 0.5ml tube. 
 
Table-2.1 Components used for mRNA-cDNA synthesis 
 
 
 
 
 
 
 
 
 
 
• The RNA/primer mixture was incubated at 65·c for 5 minutes and then placed on ice for at least 1 
minute. 
• 4. In a separation tube, the following 2X reaction mix was prepared, by adding each component in 
the  indicated order. 
 
 
 
 
 
Components Amount 
 
RNA (2μg) 
 
n μl 
 
10 mM dNTP mix 
 
1 μl 
 
 
Primer (0.5μg/μl oligo (dT)12-18) 
 
1μl 
DEPC treated water To 10μl 
 
27 | P a g e  
 
Table-2.2 Components used for mRNA-cDNA synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 9μl of the 2X reaction mixture was added to each RNA/primer mixture from step 3 and mixed gently 
and collect by briefly centrifugation. 
 
•  It was incubated at 42·c for 2 minutes. 
 
• 1μl of super scriptTM II RT was then added to each tube and Incubated at 42·c for 50 minutes 
 
 
• Then, the reaction was  terminated at 70·c for 15 minutes and chilled on ice 
 
• The reaction was collected by brief centrifugation and 1μl of RNase H was added to each tube and 
incubated for 20 minutes at 37·c. 
 
 Then, the reaction was stored at -20·c or used for PCR immediately. 
 
miRNA-cDNA synthesis 
miRNA cDNA synthesis was carried out using   NCode™ miRNA First-Strand cDNA Synthesis Kit. The 
steps involved in miRNA- cDNA synthesis were as follows 
 
 
Components 1RXn 10 RXnS 
 
10X RT buffer 
 
2 μl 20 μl 
 
25mM Mgcl2 
 
4 μl 40 μl 
 
0.1M DTT 
 
2 μl 20 μl 
 
RNase out TM (400/ μl) 
 
1 μl 10μl 
 
28 | P a g e  
 
The reaction mixture was made taking the following components- 
Table-3 Components used for miRNA-cDNA synthesis 
 
Components Amount (for 1RXN) 
5X Reaction Mix 4 μl 
10 μl Superscript enzyme mix 2 μl 
Total RNA(100pg to 1 μg) x μl 
DEPC treated water Up to 20 μl 
 
 
 
• After mixing all these components, the mixture was mixed properly through brief centrifugation. 
• The tube was then incubated at 37o C for 60 mins. 
• Then the reaction was terminated at 95o C for 5 mins and the reaction was held at 4o C until use. 
 
Quantification of mRNA  and miRNA through qRT-PCR 
Real time PCR is a method that allows exponential amplification of DNA sequences and 
simultaneously quantifies it. This system is based on the detection and quantification of a fluorescent 
probes. Probes which are used in qRT-PCR are taqman probes, molecular beacon, SYBR® Green, 
displacing probes, light up probes etc. For present study we used SYBR® Green probe which is a 
frequently used fluorescent DNA binding probe and relies on the sequence specific detection dye. For this 
experiment we have taken two sets of gene, one is the reference gene.Reference genes are used to 
compare the expression of test genes in terms of fold change with respect to normal reference gene 
expression. Reference genes are basically the house keeping genes having the same copy number in all 
cells, having their  expression  in all kind cells.   
For mRNA quantification experiment the test genes was CYR61 and reference gene used is Beta-
actin while for miRNA quantification test was miR-221 and rehference was U6 . Beta actin and U6 are the  
housekeeping genes also called as constitutive genes which are required for the maintenance of 
fundamental cellular function, and are expressed in all cells of an organism under normal and patho-
physiological conditions.  
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Quantification of mRNA  
Total master mix was prepared for two genes i.e one housekeeping gene (Beta actin) and one test 
gene(CYR61) with respect to two samples HaCaT and Hela. 
1:20 dilution was prepared for cDNA of  both infected and control sample. 
The reaction mix was prepared  taking the following components: 
 
Table-4 Components used for qRTPCR of  mRNA 
 
 
 
 
 
 
 
 
The sequence of the primer used are as follows: 
Beta actin:  Forward primer- CATGTACGTTGCTATCCAGGC 
                 Reverse primer- CTCCTTAATGTCACGCACGAT 
CYR61: Forward primer- CTCGCCTTAGTCGTCACCC 
           Reverse primer-CGCCGAAGTTGCATTCCAG 
The cycle temperature for the q-RT PCR were as follows: 
 
Figure-13 cycle temperature for mRNA q-RT PCR 
Components Amounts(for 10 μl Rxn) 
SyberGreen Mastermix 5 μl 
Forward primer  0.5 μl 
Reverse primer(10 μM) 0.5 μl 
cDNA 3 μl 
DEPC water  1μl 
30 | P a g e  
 
 
Quantification of miRNA  
Total master mix was prepared for two miRNAs i.e one reference U6 and the test has-miR-221 with 
respect to two samples HaCaT and Hela. 
Undiluted cDNA was taken for both infected and control sample. 
The reaction mix was prepared taking the following components: 
Table-5 Components used for qRTPCR of  miRNA 
 
 
 
 
 
 
 
 
 
 
 
 
         The sequence of the primer used is as follows 
          Table-6 List of primers for miRNA qRTPCR 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Components Final concentration Amount (for 10 
μlRxn) 
SyberGreen Mastermix(2X) 1X 5 μl 
Forward primer(10 μM) 200nM 0.2 μl 
Universal Reverse primer(10μM) 200nM 0.2 μl 
ROX dye(25 μM) (0.1 μM) 0.04 μl 
cDNA Up to 2 μl undiluted 1 μl 
DEPC water  3.56 μl 
Primer type Sequence 
 
hsa-miR-221-5p Forward 
 
ACCUGGCAUACAAUGUAGAUUU 
U6 Forward TGCTCGCTTCGGCAGCACATA 
 
U6 Reverse GGCGAAAGATGGAACGCTTCACGA 
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  The cycle temperature for the q-RT PCR was as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-14 cycle temperature for miRNA q-RT PCR 
 
 
 
 
 
 
 
 
  
 
 
 
 
RESULTS AND DISCUSSIONS 
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GENESPRING ANALYSIS 
Gene spring analysis of the differentially expressed micro array for mRNA data that was comprised of 10 
normal (squamous cervical epithelia) 28 Test (7 high grade squamous intraepithelial lesions &  21 inavsive 
squamous cell carcinoma) showed 338 differentially expressed mRNA out ofwhich  no. of up-regulated 
down regulated mRNA were found to be 257 and 81 respectively  with FC >=1.5. 
Similarily for miRNA data that was comprised of 10 Normal (cervical squamous epithellium) 37 Test 
sample, the analysis resulted 41 differentially expressed miRNA, out of which no. of up-regulated & down 
regulated miRNA were found to be  27 and 14 respectively  with FC>=1.5. 
The clustering analysis for both mRNAs and mRNAs showed the list of altered expressed genes as well as 
for miRNA. 
Figure-15 clustering analysis for both mRNAs showing the list of altered expressed gene 
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Interaction study by NCI pathway analysis tool 
From the NCI pathway interaction tool,CYR61 gene was found to be interesting as it is involved in various 
cell signaling pathway. 
It showed the following results:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-16  Enrichment analysis by NCI pathway analysis tool 
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Prediction of miRNA targets using Target scan 
With the help of Target scan, we found  hsa-miR-221, that targets this gene with  potential  binding sites 
(7mer-M8). 
It showed the following results: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-17  miRNA target Prediction  using Target Scan 
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EXPERIMENTAL VALIDATIONS 
RNA isolation 
mRNA Isolation: 
The yield after RNA isolation in  
HaCaT cell line  was 828.4 μg/ml, 260/280-2.03, 260/230-2.0 
The yield after RNA isolation in Hela was 870  μg/ml, 260/280-2.0, 260/230-2.08 
miRNA isolation: 
The yield after RNA isolation HaCaT cell line  was-318.4 μg/ml, 260/280-2.05, 260/230-1.90 
The yield after RNA isolation HaCaT cell line  was-476 μg/ml, 260/280-2.05, 260/230-1.79 
qRT PCR 
The melting curve for the gene CYR61 showed the following results: 
 
Figure-18 The melting curve of  CYR61 
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The melting curve for miR-221 showed the following results: 
 
Figure-19 The melting curve of  miR-221 
After calculating the Fold change by taking CT values with the formula Fold  change =2(–  ΔΔCt),the following  
graphs were  plotted for relative expression for the  miRNA as well as the gene. 
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            Figure- 20 qRT-PCR result showing upregulation of CYR61 in cervical cancer cell line 
 
 
Figure- 21 qRT-PCR  result showing downregulation of miR-221 in cervical cancer cell line. 
 
 
 
 
 
 
 
 
  
 
 
 
 
CONCLUSIONS 
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CONCLUSIONS 
From genome-wide mRNA expression analysis of cervical cancer, CYR61 was found to be down-regulated, 
but was reported to be over-expressed in other cancer systems. Therefore, we were curious to know the 
expression of this gene in cervical cancer and selected it for experimental validation. Through qRT-PCR, 
we found that CYR61 gene is over-expressed in cervical cancer. From miRNA expression analysis followed 
by target prediction by TargetScan, we identified a miRNA i.e hsa-miR-221 that targets this CYR61. To 
know its expression, we did miRNA qRT-PCR and found this miRNA to be down-regulated. As CYR61 was 
reported earlier as an angiogenesis inducing factor in most cancer systems, so we hypothesize that the 
over-expression of this gene in cervical cancer may contribute to its metastatic spread and lethality and this 
over-expression can be attributed to altered expression of miRNA-221 that might have resulted in abnormal 
expression of CYR61. The targeting of CYR61 by miR-221 can be further confirmed by luciferase reporter 
assays. Moreover, the altered expression of miR-221 may be due to promoter hypermethylation of the 
miRNA gene and can be further confirmed through methylation specific PCR of the corresponding miRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
FUTURE PROSPECTIVES 
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FUTURE PROSPECTIVES 
Based on the current findings, further studies can be performed to understand & confirm the role of miRNA 
in regulating CYR61 thereby confirming its role in angiogenesis and metastasis. Performing luciferase 
reporter assay to confirm targeting of CYR61 by miR-221 will provide evidence on the mode of regulation of 
this gene. Furthermore, investigating the role of promoter hyper-methylation of the miRNA gene through 
Methylation Specific PCR (MSP) can help us to know the root of regulation of CYR61. Understanding the 
basis of regulation of these mRNA and miRNA may provide a clue towards discovering RNA-based 
therapeutic approach for cervical cancer. Therapeutic value of this study can be further assessed by over-
expressing miR-221 in HeLa cell lines thereby checking the proliferation rate along with the expression of 
CYR61. After successful execution of these in cell lines, it can be extended further to validate in primary 
cervical stages in order to check the level of angiogenesis. Final validation is supposed to be carried by 
taking animal models. This novel approach can thus prevent the cancer progression at the initial stages 
and hence can reduce the mortality among women. 
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